The safety and efficacy of anti-diabetic drugs are critical for maximizing the beneficial impacts of well-controlled blood glucose on the prognosis of individuals with COVID-19 and pre-existing type 2 diabetes (T2D). Metformin is the most commonly prescribed first-line medication for T2D, but its impact on the outcomes of individuals with COVID-19 and T2D remains to be clarified. Our current retrospective study in a cohort of 1,213 hospitalized individuals with COVID-19 and pre-existing T2D indicated that metformin use was significantly associated with a higher incidence of acidosis, particularly in cases with severe COVID-19, but not with 28-day COVID-19-related mortality. Furthermore, metformin use was significantly associated with reduced heart failure and inflammation. Our findings provide clinical evidence in support of continuing metformin treatment in individuals with COVID-19 and pre-existing T2D, but acidosis and kidney function should be carefully monitored in individuals with severe COVID-19.

抗糖尿病药的安全性和有效性对于最大限度地控制血糖对COVID-19和已有2型糖尿病（T2D）患者的预后至关重要。二甲双胍是T2D最常用的一线药物，但其对COVID-19和T2D患者预后的影响尚待阐明。我们目前的一项回顾性研究是对1,213名住院的COVID-19和既往已患有T2D的患者进行的一项队列研究，结果表明二甲双胍的使用与酸中毒的发生率显着相关，特别是在严重COVID-19的情况下，但与28天的COVID无关-19相关的死亡率。此外，二甲双胍的使用与减少心力衰竭和炎症显着相关。